What Atsena Therapeutics does

Atsena Therapeutics is a clinical-stage gene therapy company developing adeno-associated virus (AAV)-based treatments for inherited retinal diseases that currently have no approved therapies. The company's pipeline targets X-linked retinoschisis (XLRS, lead program ATSN-201 in pivotal Phase 3), GUCY2D-associated Leber congenital amaurosis type 1 (LCA1, ATSN-101 in Phase 1/2 with global Phase 3 planned H2 2026), MYO7A-associated Usher syndrome type 1B (ATSN-301, preclinical, using dual-vector technology), and Stargardt disease (ATSN-401, preclinical), plus undisclosed preclinical candidates. The pipeline is powered by a proprietary AAV technology platform comprising three differentiated components: AAV.SPR (a laterally spreading capsid that enables foveal transduction from a peripheral injection without surgical foveal detachment, transducing up to 99% of foveal cones in non-human primates), dual AAV vector technology for delivery of large genes exceeding single-vector capacity, and engineered intravitreal capsids designed to evade pre-existing neutralizing antibodies. The company has accumulated an unusually dense regulatory designation stack: ATSN-201 holds FDA RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug Designations plus EMA Orphan Designation, while ATSN-101 holds FDA RMAT, RPD, and Orphan Drug Designations.

The company is pre-revenue with no commercial products on market. Its business model anticipates revenue from one-time administration of approved gene therapy products through a specialty treatment-center network mirroring the rare-disease gene therapy commercial archetype (e.g., Luxturna at ~$425K per eye as a directional reference). Go-to-market relies on direct engagement with retinal disease specialists at leading academic medical centers across North America and Europe, supported by clinical-trial-site activation, KOL relationships, and patient-advocacy partnerships (notably Foundation Fighting Blindness, Hope in Focus, and Usher Syndrome Coalition). Commercial readiness is being built via a strategic partnership with Nippon Shinyaku (ATSN-101 rights in U.S. and Japan, with Atsena retaining rest-of-world rights) and a commercial manufacturing agreement with Genezen for AAV supply. Atsena is incorporated in Delaware, headquartered in Durham, North Carolina, and has raised approximately $215 million in cumulative disclosed funding across seed/Series 1 ($8.15M, 2020), Series A ($55M, 2020), an exempt offering (~$24.5M, 2023), and Series C ($150M, April 2025, led by Bain Capital Life Sciences).

Name

Atsena Therapeutics

Legal name

Atsena Therapeutics Inc.

Website

https://atsenatx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Atsena Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases (XLRS, LCA1, USH1B), targeting rare-disease patient populations with no approved therapies and targeting a BLA filing in 2H 2028 for its lead program ATSN-201.

Ownership category

akta.pro rank

Product category

Ocular Gene Therapy Pharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Ocular gene therapy
• AAV gene therapy platform
• Inherited retinal disease treatments
• Rare ophthalmology therapeutics
• Subretinal gene delivery

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Gene therapy product sales (future): As a pre-commercial clinical-stage company, Atsena currently has no product revenue. The company is developing gene therapy candidates for rare inherited retinal diseases and plans to commercialize these upon regulatory approval. ATSN-201 for XLRS is in pivotal Phase 3 with BLA filing targeted for 2H 2028. Revenue will come from sales of approved gene therapy products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Atsena Therapeutics is a clinical-stage gene therapy company developing investigational AAV-based gene therapies for inherited forms of blindness. Its lead product candidates include ATSN-201 for X-linked retinoschisis (currently in pivotal Phase 3), ATSN-101 for GUCY2D-associated Leber congenital amaurosis type 1, and ATSN-301 for MYO7A-associated Usher syndrome type 1B, all powered by its proprietary AAV technology platform (laterally spreading capsids, dual vector technology, and engineered intravitreal capsids).

Product overview

Atsena Therapeutics is a clinical-stage gene therapy company developing a portfolio of gene therapies for inherited retinal diseases. The company's pipeline includes lead program ATSN-201 (for X-linked retinoschisis) in pivotal Phase 3, ATSN-101 (for LCA1) completing Phase 1/2 with Phase 3 planned, ATSN-301 (for Usher Syndrome 1B) in preclinical stage, and ATSN-401 (for Stargardt Disease) also preclinical. The pipeline is powered by the company's proprietary AAV technology platform including laterally spreading capsids (AAV.SPR), dual vector technology, and intravitreal capsids.

Differentiator

Problem solved

Functional benefit

Products and services

• ATSN-201 Investigational AAV.SPR-based gene therapy for X-linked retinoschisis (XLRS), a monogenic eye disease causing progressive vision loss. Designed to enable safe delivery to the fovea without surgical detachment. Currently in Phase 3 pivotal cohort of the LIGHTHOUSE trial with BLA filing targeted for second half of 2028.
• ATSN-101 First-in-class investigational subretinal AAV5 gene therapy for Leber congenital amaurosis type 1 (LCA1) caused by GUCY2D mutations. Phase 1/2 trial completed with positive results including ~20 decibel (~100-fold) mean improvement in dark-adapted FST durable through at least 3 years. Global pivotal Phase 3 planned for H2 2026.
• ATSN-301 Dual AAV vector-based investigational gene therapy for MYO7A-associated Usher syndrome type 1B (USH1B), an inherited disease affecting both retina and inner ear (deafness and progressive blindness). Preclinical stage; targets a ~6.6 kb gene payload that exceeds single-vector capacity.
• ATSN-401 Preclinical gene therapy candidate for Stargardt disease (STGD), a hereditary condition causing progressive vision loss. Currently in preclinical development.

Quantifiable outcome

• Phase 1/2 data: 7 of 9 treated eyes showed foveal schisis closure at 12 months; statistically significant improvements in microperimetry, BCVA, and low-luminance VA; no drug-related serious adverse events.
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• GenezencoreImplementation/ SI/ Consulting Partner · 20 January 2026Strategic commercial manufacturing partnership between Genezen (gene therapy CDMO) and Atsena for clinical development and commercial manufacturing of Atsena's pipeline programs. Genezen leverages its viral vector manufacturing expertise and facilities to support Atsena's AAV-based gene therapy products. The partnership is designed to provide a streamlined and cost-efficient path to commercial manufacturing for Atsena's gene therapy products, including ATSN-201 which is targeted for BLA filing in early 2028.
• Nippon ShinyakucoreStrategic or Co-development Partner · 13 November 2024Exclusive strategic collaboration for ATSN-101 (gene therapy for GUCY2D-associated LCA1) in the U.S. and Japan. Nippon Shinyaku holds exclusive commercial rights in the U.S. and Japan, while Atsena retains commercial rights in the rest of the world. Atsena expects to initiate a global pivotal Phase 3 clinical trial for ATSN-101 in the second half of 2026.
• University of FloridacoreTechnology or IntegrationUniversity of Florida is a key research partner and co-founder origin institution. Atsena was co-founded by Dr. Shannon Boye and Sanford Boye from UF's Powell Gene Therapy Center. The company's technology originated from over 20 years of AAV and ocular gene therapy research at UF, including foundational work on GUCY2D-LCA1 gene therapy and AAV capsid development.
• Foundation Fighting BlindnesscoreStrategic or Co-development PartnerFoundation Fighting Blindness (FFB) is a key patient advocacy and research partner. Dr. Benjamin Yerxa (CEO of FFB) serves on Atsena's Scientific Advisory Board. FFB provides funding, patient community engagement, and research collaboration support for inherited retinal disease gene therapy development.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Coave Therapeutics: Coave Therapeutics (formerly Horama) is a clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases, including programs for RPGR-XLRP and CRB1 retinitis pigmentosa. Direct adjacency as a niche European-origin AAV retinal gene therapy competitor with platform technologies competing for similar retinal specialist relationships.
• ProQR Therapeutics: ProQR develops RNA-editing therapeutics (Axiomer platform) for genetic eye diseases including LCA10 and Usher syndrome. Comparable as an emerging player targeting the same inherited retinal disease patient populations via a different mechanism (RNA editing vs. AAV gene replacement), creating both partnership and competitive dynamics for ocular genetic medicine specialists.
• AAVantgarde Bio: AAVantgarde Bio is a clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases and other genetic disorders, founded on dual AAV vector platform concepts similar to Atsena's technology. Emerging competitor in the same rare inherited retinal disease therapeutic space with comparable capsid engineering focus.
• Editas Medicine: Editas is a clinical-stage CRISPR gene-editing company with ophthalmology programs (e.g., EDIT-101 for LCA10) that compete with AAV gene therapy approaches to inherited retinal disease. Comparable as an emerging player in the inherited retinal disease genetic medicine space, with a different mechanism (editing vs. AAV delivery) but the same target customer base of retinal specialists.

Direct peers

• Spark Therapeutics (Roche): Spark created and commercialized Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65-LCA). Spark is the most directly comparable ocular AAV gene therapy company, validating both the therapeutic class and the ultra-rare ophthalmology gene therapy commercial model that Atsena targets with ATSN-201 and ATSN-101.
• MeiraGTx: MeiraGTx is a clinical-stage gene therapy company with multiple inherited retinal disease programs (e.g., AAV5-GUCY2D for LCA1 — directly overlapping Atsena's ATSN-101 program), plus wholly-owned manufacturing capabilities. Direct peer in ocular AAV gene therapy with overlapping LCA1 indication.
• Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company focused on cardiovascular and ocular diseases, with programs in CLN3 (Batten disease) and other inherited disorders. Comparable as a clinical-stage AAV gene therapy company tackling rare inherited diseases with similar regulatory pathway and CDMO-manufactured AAV pipeline economics.
• Adverum Biotechnologies: Adverum develops AAV-based gene therapies for ocular diseases, with lead program ixoberogene soroparvovec (ixo-cel) for wet AMD targeting the same intravitreal delivery model Atsena is engineering with its intravitreal capsids. Closely comparable as a clinical-stage ocular AAV gene therapy company competing for partnerships and commercial eye care infrastructure.

Others

• Krystal Biotech: Krystal Biotech is a commercial-stage gene therapy company (Vyjuvek for DEB) that demonstrates the commercial and regulatory playbook for ultra-rare disease AAV gene therapy, including direct-to-patient commercial infrastructure and self-funded CMC. Adjacent as a public comp for valuation of clinical-to-commercial-stage gene therapy companies, though its therapeutic area (dermatology) does not directly overlap Atsena's ophthalmology focus.

Broad incumbents

• REGENXBIO: REGENXBIO operates a broader AAV gene therapy platform with multiple ocular and CNS programs, plus partnered assets with AbbVie and others. It is a more diversified incumbent in AAV gene therapy whose NAV technology and partnered retinal programs (e.g., RGX-314 for wet AMD) provide relevant comparables on vector platform valuation, while not specializing exclusively in inherited retinal disease like Atsena.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/atsenatx

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atsena Therapeutics